Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus PROMETHAZINE VC W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus PROMETHAZINE VC W CODEINE.
ACTIDIL vs PROMETHAZINE VC W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic